ICP-192 not checked
Beijing InnoCare Pharma Tech Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Intrahepatic Cholangiocarcinoma (ICC)
- Main trialPhase 2
- “This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy”In the company’s words, NCT05678270 on ClinicalTrials.gov
Other drugs for Intrahepatic Cholangiocarcinoma (ICC)
- FutibatinibTaiho · Phase 2/3
- TinengotinibTransThera Sciences (Nanjing), Inc. · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | May 2026 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | |
| Phase 2Unknown | 31 Dec 2023 | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | |
| Phase 2Unknown | 31 Dec 2024 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | |
| Phase 1/2Unknown | 30 Nov 2023 | A Study of ICP-192 in Patients With Advanced Solid Tumors | |
| Phase 1/2Unknown | 31 Dec 2024 | Clinical Study of ICP-192 in Solid Tumors Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026